Mast cells as a therapeutic target in myeloproliferative neoplasms

Méndez-Ferrer, 2020, Bone marrow niches in haematological malignancies, Nat. Rev. Cancer, 20, 285, 10.1038/s41568-020-0245-2 Bradding, 2018, The controversial role of mast cells in fibrosis, Immunol. Rev., 282, 198, 10.1111/imr.12626 Gotlib, 2021, Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial, Nat. Med., 27, 2192, 10.1038/s41591-021-01539-8 Ishii, 2009, Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders, Blood, 113, 5942, 10.1182/blood-2008-09-179416 Wang, 2009, Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms, Leukemia, 23, 1577, 10.1038/leu.2009.85 Keski, 2020, Association of mast cells and bone marrow reticulin fibrosis in patients with bcr-abl negative chronic myeloproliferative neoplasms, Blood Cells Mol. Dis., 82, 10.1016/j.bcmd.2020.102420 Melo-Cardenas, 2021, IL13 contributes to fibrotic progression of the myeloproliferative neoplasms, Blood, 138, 60, 10.1182/blood-2021-151492 Toledo, 2021, Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis, Blood, 137, 2070, 10.1182/blood.2019004509 Vannucchi, 2015, Ruxolitinib versus standard therapy for the treatment of polycythemia vera, N. Engl. J. Med., 372, 426, 10.1056/NEJMoa1409002 Verstovsek, 2012, A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis, N. Engl. J. Med., 366, 799, 10.1056/NEJMoa1110557 Hermans, 2018, The JAK1/JAK2– inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release, Clin. Exp. Allergy, 48, 1412, 10.1111/cea.13217 Overed-Sayer, 2020, Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects, Thorax, 75, 754, 10.1136/thoraxjnl-2019-214000